MedTrace Logo

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

NCT03815682 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-12-06

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.

Conditions

Interventions

BIOLOGICAL

Arm A: RPTR-147:1

Escalating doses of RPTR-147:1 as a monotherapy

BIOLOGICAL

Arm B: RPTR-147:1 and Pembrolizumab

Escalating doses of RPTR-147:1 in combination with Pembrolizumab

BIOLOGICAL

Arm C: RPTR-147:2

Escalating doses of RPTR-147:2 in patients with HPV positive tumors

Sponsors & Collaborators

Principal Investigators

  • David Spriggs, MD · Repertoire Immune Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-24
Primary Completion
2022-09-07
Completion
2022-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03815682 on ClinicalTrials.gov